Details

Telomere length and oxidative stress in small cell lung cancer patients : changes through chemotherapy cycles compared to healthy controls
ID Guzonjić, Azra (Author), ID Jovanovic, Dragana (Author), ID Šimić, Ivana (Author), ID Ceriman, Vesna (Author), ID Samardzić, Natalija (Author), ID Ostanek, Barbara (Author), ID Marc, Janja (Author), ID Sopić D., Miron (Author), ID Kotur Stevuljević, Jelena (Author)

.pdfPDF - Presentation file, Download (211,54 KB)
MD5: AAD39BDF65ADACACBB41F0522F3C0406
URLURL - Source URL, Visit https://biochemia-medica.com/en/journal/35/2/10.11613/BM.2025.020705 This link opens in a new window

Abstract
Introduction: Small cell lung cancer (SCLC) is an aggressive malignant disease with poor survival outcomes. The aim of this study was to investigate leukocyte telomere length (LTL) and redox status parameters during chemotherapy and evaluate their prognostic potential based on the hypothesis that shorter LTL and oxidative stress burden correlate with poorer survival. Materials and methods: This longitudinal study included 60 SCLC patients and 73 healthy controls. Leukocyte telomere length was measured by quantitative PCR (qPCR) method, while redox status parameters (MDA - malondialdehyde, IMA - ischemia-modified albumin, PON1 - paraoxonase 1, redox index) were determined by spectrophotometric methods before, after two and after four cycles of chemotherapy. Results: All measured parameters showed significant differences between patients and controls, except the oxy-score (P < 0.001). Significant differences in IMA, PON1 and redox index were observed between SCLC patient groups at different time points (P < 0.001). Significant differences in IMA and PON1 were observed between SCLC survival groups, with higher values found in survivors after two chemotherapy cycles (P < 0.001). Redox index was the highest in the pre-chemo group (P = 0.019). Among patients who died, PON1 activity differed significantly between those who died within 2 months and after 4 months (P = 0.028). Kaplan-Meier analysis showed that LTL and PON1 were significant predictors of survival, with values below the 25th percentile associated with a higher risk of death. Conclusions: Leukocyte telomere length and PON1 are potential prognostic biomarkers for SCLC survival, suggesting their potential use in non-invasive biomarker panels for improved patient stratification.

Language:English
Keywords:telomere length, redox status, small cell lung cancer, cisplatin/etoposide regimen
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2025
Number of pages:12 str.
Numbering:Vol. 35, issue 2, art. 020705
PID:20.500.12556/RUL-168504 This link opens in a new window
UDC:616.24-006
ISSN on article:1846-7482
DOI:10.11613/BM.2025.020705 This link opens in a new window
COBISS.SI-ID:232858115 This link opens in a new window
Publication date in RUL:16.04.2025
Views:727
Downloads:265
Metadata:XML DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Biochemia medica
Shortened title:Biochem. med.
Publisher:Hrvatsko društvo medicinskih biotehničara, Medicinska naklada
ISSN:1846-7482
COBISS.SI-ID:4744255 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:dolžina telomera, redoks stanje, drobnocelični pljučni rak, režim cisplatin/etopozid, rak (medicina), pljuča

Projects

Funder:Other - Other funder or multiple funders
Funding programme:Ministry of Science, Technological Development, and Innovation of the Republic of Serbia
Project number:451-03-65/2024-03/ 200161
Name:Grant Agreement with University of Belgrade (Faculty of Pharmacy)

Funder:Other - Other funder or multiple funders
Funding programme:Ministry of Science, Technological Development, and Innovation of the Republic of Serbia
Project number:451-03-66/2024-03/ 200161
Name:Grant Agreement with University of Belgrade (Faculty of Pharmacy)

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back